We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Ultrastructure of Atrial Myocytes in Patients in Sinus Rhythm and With Atrial Fibrillation

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT01493128
First Posted: December 15, 2011
Last Update Posted: March 13, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
Norwegian University of Science and Technology
  Purpose

The aim of this work is to study the prevalence of T-tubular system in left and right myocytes from patients in sinus rhythm and whether this is altered in paroxysmal and permanent atrial fibrillation. Furthermore, since current information is lacking on the key Ca2+-handling proteins RyR, NCX, and SERCA-2a from patients in Atrial Fibrillation (AF), it will be investigated whether a regulation of these proteins could be an underlying cause of the disease. Mitochondrial function will also studied.

  1. The investigators hypothesize that both structure of sarcolemma and localization of key Ca2+-handling proteins are altered in patients with atrial fibrillation compared with patients in sinus rhythm.
  2. The investigators hypothesize that mitochondrial function is altered in patients with atrial fibrillation compared with patients in sinus rhythm.

Condition
Atrial Fibrillation

Study Type: Observational
Study Design: Observational Model: Case-Control
Time Perspective: Cross-Sectional
Official Title: Ultrastructure of Sarcolemma, Immunofluorescence of Calcium Handling Proteins and Mitochondrial Function in Atrial Myocytes of Patients in Sinus Rhythm and With Atrial Fibrillation

Resource links provided by NLM:


Further study details as provided by Norwegian University of Science and Technology:

Primary Outcome Measures:
  • structure of sarcolemma [ Time Frame: 1 hour ]

Biospecimen Retention:   Samples Without DNA
Myocardial tissue from the right and left atrial appendage.

Enrollment: 45
Actual Study Start Date: April 2010
Study Completion Date: July 2012
Primary Completion Date: February 2012 (Final data collection date for primary outcome measure)
Groups/Cohorts
stable sinus rhythm
permanent atrial fibrillation
paroxysmal atrial fibrillation

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   50 Years to 85 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
selected for open heart surgery in St Olavs Hospital, Trondheim University Hospital, Norway
Criteria

Inclusion Criteria:

  • sinus rhythm, permanent atrial fibrillation or paroxysmal atrial fibrillation
  • selected for open heart surgery
  • informed consent

Exclusion Criteria:

  • not given informed consent
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01493128


Sponsors and Collaborators
Norwegian University of Science and Technology
Investigators
Study Director: Ulrik Wisløff, PhD Norwegian University of Science and Technology
  More Information

Publications:
Responsible Party: Norwegian University of Science and Technology
ClinicalTrials.gov Identifier: NCT01493128     History of Changes
Other Study ID Numbers: ABJ01
First Submitted: December 13, 2011
First Posted: December 15, 2011
Last Update Posted: March 13, 2017
Last Verified: March 2017

Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No

Keywords provided by Norwegian University of Science and Technology:
atrial fibrillation
atrial cells
myocardial tissue
t-tubules
immunofluorescence

Additional relevant MeSH terms:
Atrial Fibrillation
Arrhythmias, Cardiac
Heart Diseases
Cardiovascular Diseases
Pathologic Processes


To Top